Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00472_DB00543_nanopub.RA1QCoiKSOAdpEN0XcVNGHuTtPxxua-tuv9YzdtBh2jNc#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00472_DB00543 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00472_DB00543 label "DDI between Fluoxetine and Amoxapine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB00543]" assertion.
- drugbank_resource:DB00472_DB00543 identifier "drugbank_resource:DB00472_DB00543" assertion.
- drugbank_resource:DB00472_DB00543 title "DDI between Fluoxetine and Amoxapine - The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00472 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB00543 assertion.
- drugbank:DB00543 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00472_DB00543 assertion.